Jane Street’s Monopar Therapeutics MNPR Stock Holding History

Jane Street’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,357	Closed	-$377K	–	10413
2025 Q1	$377K	Buy	+10,357	New	+$373K	﹤0.01%	7404

Other funds holding MNPR

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's MNPR Position: Q2 2025 in Review

Jane Street sold out of Monopar Therapeutics (MNPR) in Q2 2025, closing a stake of 10,357 shares — an estimated $377K sold.

Jane Street first reported a position in MNPR in Q1 2025 and held it in 1 quarter. The position peaked at $377K in Q1 2025. 43 funds tracked by Wall St. Rank hold MNPR as of Q2 2025.

Jane Street reported no remaining Monopar Therapeutics position as of Q2 2025 after selling out during the quarter.
Jane Street sold 10,357 Monopar Therapeutics shares in Q2 2025, an estimated $377K.
Jane Street first reported a position in Monopar Therapeutics in Q1 2025 and held it in 1 quarter.
Jane Street's Monopar Therapeutics position peaked at $377K in Q1 2025.
43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.